Articles tagged with Human Immunodeficiency Virus
Advances in HIV care have yielded a total survival benefit of 2.8 million years in the US, saving an additional 137,000 years of life through mother-to-child transmission prevention. The study found that HIV therapies have transformed the disease from a rapidly fatal condition to a controllable one.
The Infectious Diseases Society of America calls for routine HIV testing to identify those who need treatment. Early testing and connection with care can save millions more lives beyond the three million already saved through antiretroviral therapy.
Researchers at FSU have produced high-resolution images of the HIV virus, revealing its complex molecular surface architecture and enabling the development of more effective vaccines. The study, published in Nature, provides valuable insights into the virus's structure and behavior, which could lead to breakthroughs in vaccine design.
A recent study published in AIDS Education and Prevention found that few HIV-positive gay men regret sharing their diagnosis with friends and family. In fact, only 4.2% of participants reported regret after disclosing their status to at least one social network member.
A study found that patients with HIV-HBV coinfection can successfully undergo liver transplantation without progression of viral disease, even in the setting of lamivudine resistance. Controlling HBV is crucial for survival, and ongoing monitoring will be essential to minimize liver-related complications.
A new study will develop a cohort of 1,000 HIV-infected IDUs with a history of injection drug use to examine treatment access and adherence. The research aims to improve access to life-saving HIV and HCV treatments for marginalized individuals in Vancouver's Downtown Eastside.
Researchers will investigate whether liver damage in HIV patients with hepatitis C is caused by the medication or the virus itself. The goal of the study is to improve treatment outcomes for patients with both conditions.
The US government's PEPFAR program aims to prevent 7 million new HIV infections by 2010, but a GAO report reveals that an ambiguous approach to condom promotion may hinder its success. Promoting condoms alongside abstinence and faithfulness messages is crucial for reaching this target.
A study assessing combined interventions found co-trimoxazole, ART, and insecticide-treated bed nets substantially reduced malaria frequency in HIV-infected adults. The treatments had a cumulative protective effect on malaria incidence, with co-trimoxazole lowering rates by 76%, ART and co-trimoxazole by 92%, and all three by 95%.
A new study by Johns Hopkins Medicine researchers suggests that a commercially available antibiotic, ceftriaxone, may be effective in fighting dementia in HIV patients. The study found that ceftriaxone protected human neuronal cells from the effects of HIV proteins Tat and gp120.
A University of Toronto study found HIV infection rates declining in South India, likely due to increased condom use and awareness programs. The study tracked data from antenatal clinics, showing a significant decrease in new infections among young adults.
TB researchers hope to find novel ways of killing the organism using a protective protein called heme oxygenase 1. The project aims to pinpoint the role of alcoholism in the global epidemic by studying HIV- and tuberculosis-infected patients in India.
A study published in Archives of Dermatology found that injecting polylactic acid can safely and effectively treat facial lipoatrophy in HIV patients, improving skin and fat thickness over 12 months. The treatment showed significant results, with increased dermal thickness persisting beyond the initial six injections.
Scientists have discovered a way to increase HIV-1 p24 protein production in plants using antibody-antigen fusion molecules, potentially leading to cheaper and more effective vaccines. This technology could also pave the way for mass-producing plant-derived pharmaceuticals for poor populations in developing countries.
Two DNA repair proteins, XPB and XPD, can destroy HIV DNA, reducing viral replication and integration into host chromosomes. This finding may lead to new strategies for treating HIV infection and AIDS.
A study analyzing healthcare utilization data for HIV-infected patients found that HAART is cost-effective as long as patients stick to treatment. However, the study also revealed significant disparities in healthcare costs between healthier and sicker patients, highlighting inadequate reimbursement to treating physicians and clinics.
Researchers found combined therapy improved survival rates for patients with AIDS-related lymphoma, comparable to non-HIV patients with lymphoma treated with CHOP. For standard-risk ARL patients, 79% achieved complete remission and 50% survived after 47 months.
A study by University of Illinois Chicago found that mothers teaching their daughters about HIV and sexual health can significantly reduce high-risk behavior. The Mother/Daughter HIV Risk Reduction program, which included joint mother/daughter homework assignments and abstinence agreements, was more effective than other interventions.
Researchers found a significant decline in HIV prevalence in some groups, with a 49% drop for women aged 15-24 and a 23% drop for men aged 17-29. Behavioral changes, including delayed sex and fewer casual partners, are believed to be the main reason for this decline.
A Duke University Medical Center study found that free HIV tests are more cost-effective in preventing infections, drawing in three times as many people for testing. The research showed that the cost of prevention dropped from $170 to $92 per person when testing rates increased.
The study found that non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant viruses have an advantage over sensitive viruses even at low levels of adherence. NNRTI and protease inhibitors are potent antiretroviral drugs with demonstrated effectiveness when taken as directed.
Researchers have discovered a novel strategy for enhancing HIV vaccination by silencing the SOCS1 molecule in dendritic cells, which can induce a good memory immune response and boost the potency of HIV DNA vaccination. This approach has potential for therapeutic and prophylactic vaccines against HIV and other pathogens.
A new HIV vaccine strategy involves removing the natural immune system's 'brake' to enhance anti-HIV responses, showing promise for improved treatment and prevention. The approach uses a molecule called SOCS1 to regulate immune cells and boost antibody and T-cell responses.
A study found that adolescent daughters of parents with HIV have a high childbearing rate, with 38-67% experiencing pregnancy. Interventions like family-based counseling and academic support reduced the likelihood of early childbearing.
The Children's Hospital of Philadelphia has received a four-year, $6.7 million grant to study novel HIV therapy targeting neurokinin-1 receptors. The program aims to block the virus from immune cells, improve innate immune function, and reduce symptoms of depression associated with the disease.
Research examines how drug policy affects incarceration rates and HIV infection levels among African Americans, who make up 40% of those incarcerated and 50% of new HIV diagnoses. The study calls for further research on the corrections system's impact on HIV risk and recommends investigating specific components of drug policy.
A pilot study finds that a jewelry-making program significantly reduces HIV risk and increases self-esteem among Baltimore women involved in prostitution. The program also generates income through public sales, with participants earning over $7,000.
Researchers at the University of Pennsylvania School of Medicine have discovered a human DNA-associated protein called LEDGF that controls where HIV integrates into human chromosomes. This finding has significant implications for improving the design of gene-therapy delivery systems.
A study of over 3,900 children with HIV found that total lymphocyte count can predict disease progression as well as CD4 cell percentage. The current WHO guidelines for starting ART are inconsistent and may lead to inadequate treatment in low-income countries.
Researchers found a link between placental microtransfusions and HIV transmission in mothers, particularly during vaginal delivery. The study suggests that better understanding of microtransfusions could lead to more effective treatments for preventing mother-to-child transmission of HIV.
A recent study found that 76% of treatment-experienced patients would consider using a self-injectable HIV therapy if recommended by their physician. Despite this, only one quarter of eligible patients have discussed the option with their doctors, highlighting a significant barrier to adoption.
Researchers found that HAART can reduce the risk of tuberculosis in HIV patients, but not eliminate it. Patients who are immunodeficient or exposed to TB in a hospital setting are at increased risk of developing active TB.
Researchers found HIV-infected patients with effective antiviral therapy continually replenish their viral reservoir. Latently infected CD4+ T cells may become reactivated, spreading virions to nearby cells. A new strategy involves co-administering a reagent to dampen cellular activation.
Research reveals that Asian immigrant religious institutions in NYC are often uninformed about HIV prevention and care, with leaders citing cultural and moral taboos as barriers to involvement. Despite this, many acknowledge the importance of promoting general health and community service.
Researchers identified a human milk component that blocks HIV interaction with dendritic cells and inhibits viral transfer to CD4+ T-lymphocytes. This discovery has significant implications for developing agents to block HIV transmission.
The introduction of generic ART led to a significant decline in HIV-related deaths in India between 1997 and 2003. Accessible drugs have also reduced the incidence of opportunistic infections such as tuberculosis among immunocompromised patients.
Researchers identify a key pathway for targeting pDC function in HIV vaccine development. A decrease in blood pDC frequency is observed in chronic HIV infections, correlating with high viral load and reduced CD4 counts.
A multi-center study of 425 HIV-positive men found that central fat loss was statistically associated with peripheral fat loss in HIV-positive men on retroviral therapy. Central fat gain was also less among HIV-positive men, with age being the strongest factor associated with increased visceral fat.
An international team of researchers suggests that people at high risk of contracting HIV should take daily antiretroviral medication as a preventative measure. This approach, known as PrEP, has been shown promise in clinical trials and is seen as a crucial strategy to combat the ongoing pandemic.
Scientists at Vanderbilt University Medical Center discovered compounds secreted by frog skin can selectively kill HIV without harming T cells. The findings hold promise for developing new treatments and vaccines against the virus.
A study in Rakai, Uganda found that women are at a higher risk of HIV infection during pregnancy compared to other times. The risk remains significant even after adjusting for sociodemographic or behavioral factors.
A new study from Uganda found that pregnant women are at a higher risk of acquiring HIV, with rates of 2.3% per year during pregnancy compared to 1.3% during breastfeeding and 1.1% for non-pregnant women. The research suggests hormonal changes may contribute to this increased risk.
Robert Gallo emphasizes the need for a rational approach to HIV vaccine development, ignoring empirically driven methods and focusing on solid knowledge of HIV biology. He suggests leveraging the Gates's Foundation's Grand Challenge for Global Health to find practical solutions to scientific roadblocks.
Research suggests that performing genotype resistance testing at the time of HIV diagnosis can guide treatment choices, increasing patient survival by over 14 months. The cost-effectiveness analysis indicates a cost of $23,900 per quality-adjusted life year gained, comparable to other HIV interventions.
A study found that HIV-infected patients with mild memory loss who used the Disease Management Assistance System (DMAS) Jerry took their medication 80% of the time, compared to 65% without it. This improvement was seen in both normal and memory-impaired patients.
A new study confirms that APOBEC-3G edits the HIV genetic code, preventing viral reproduction. Higher levels of A3G are associated with lower HIV viral levels and higher CD4 T cell counts in patients. This discovery holds promise for a novel approach to fight HIV.
The article highlights the need for further research on HIV and aging, citing concerns over delayed diagnoses and inadequate treatment. Older patients with HIV may experience increased mortality rates and unique side effects from HAART treatment due to age-related factors.
Researchers employed a bacteriophage to learn how an HIV protein responds to new anti-viral molecules, identifying compounds with potential to overcome drug resistance. This approach enables faster and more effective drug discovery for other anti-viral therapies.
A Penn physician argues that explicit consent is not necessary for HIV testing in critically ill patients, as it can lead to earlier application of life-saving therapies and reduce costs. Alternative methods, such as surrogate consent or court-ordered testing, may be more effective but also pose challenges.
A recent study found that HIV therapy success rates are similar between developed and non-developed countries, with a general success rate of 60% after 12-18 months on treatment. People in developing countries who received free ART drugs showed a 30% higher rate of success than those who had to pay for their medication.
A study of over 3,200 HIV patients found that HAART substantially reduces the rate of AIDS progression by 86% compared to no treatment. The effectiveness of HAART increases with time since initiation, but its benefits are reduced for patients who contracted HIV through intravenous drug use.
A study found that antiretroviral therapy can suppress HIV RNA in breast milk, reducing mother-to-child transmission. However, the impact of therapy on HIV DNA levels is unclear, with some studies suggesting a possible delay in treatment's effectiveness.
Random fluctuations in gene expression can influence HIV latency, suggesting that a cell's fate is determined by chance rather than predetermined mechanisms. The researchers' model suggests that targeting chemical modifications required for Tat's function could lead to new treatments.
Studies show that FUZEON combined with tipranavir achieves a ten-fold reduction in viral load and double the increase in immune cell count. The 'FUZEON effect' has been seen across multiple studies, nearly doubling patients reaching undetectable viral loads.
A new study in PLoS Pathogens found that HIV's Vif protein exhibits natural variation, which can impact its ability to replicate. This variability may accelerate the evolution of the virus by partially or fully inactivating host defensive proteins.
A new, low-cost device can accurately count CD4 cells in HIV-infected individuals, enabling early treatment decisions and improving patient outcomes. The portable handheld model is designed for healthcare workers in remote areas, addressing a critical need in low-income countries.
Researchers find HIV domains mediate cell membrane fusion and downregulate T-cell responses. The study also suggests a novel way to decrease undesirable immune responses, independent of HIV infection.
The USPSTF has issued new recommendations for HIV screening, which will be posted on the journal's website and the Agency for Health Care Research and Quality's website. The Task Force recommends testing for all individuals at risk of HIV infection, as well as pregnant women to prevent mother-to-child transmission of AIDS.
A new review of 10 studies on HIV treatment programs in developing countries found that nearly 57% of patients had undetectable HIV levels one year after starting ART. Free or low-cost ART programs have been shown to improve adherence and treatment outcomes, suggesting a significant link between access and success.
A team of researchers has identified an intermediate stage in virus-cell fusion that lasts several minutes, providing a potential window of opportunity for drug development. This discovery may allow existing drugs to be re-evaluated and fine-tuned to target this critical point in the viral entry process.